OREANDA-NEWS. Pfizer Inc. (NYSE: PFE) reported financial results for fourthquarter and full-year 2014. At the beginning of fiscal year 2014, the company began managing its commercial
operations through a new global commercial structure consisting of two distinct businesses: an Innovative Products business and an Established Products business. The Innovative Products business is composed of two operating segments: the Global Innovative Pharmaceutical segment (GIP)(3) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC)(3). The Established Products business consists of the Global Established Pharmaceutical segment (GEP)(3). Financial results for each of these segments are presented in the Operating Segment Information section.

As a result of the full disposition of Zoetis Inc. (Zoetis) on June 24, 2013, the financial results of the Animal Health business are reported as a discontinued peration in the consolidated statements of income for the twelve months ended December 31, 2013.

Some amounts in this press release may not add due to rounding. All percentages have been calculated using unrounded amounts. Results are summarized below.

OVERALL RESULTS

(\$ in millions, except
per share amounts)                                                                 Fourth-Quarter                                                         Full-Year
                                                                                             2014 2013 Change                                           2014 2013 Change
Reported Revenues(1)                                                 \$ 13,118 \$ 13,558 (3%)                                           \$ 49,605 \$ 51,584 (4%)
Adjusted Income(2)                                                              3,441 3,686 (7%)                                                 14,530 15,288 (5%)
Adjusted Diluted EPS(2)                                                           0.54 0.56 (4%)                                                         2.26 2.22 (2%)
Reported Net Income(1)                                                       1,228 2,568 (52%)                                                9,135 22,003 (58%)
Reported Diluted EPS(1)                                                          0.19 0.39 (51%)                                                      1.42 3.19 (55%)